Stay updated on Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.

Latest updates to the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page
- Check5 days agoChange DetectedThe page’s displayed platform/footer revision was updated from v3.5.2 to v3.5.3, reflecting a site version change rather than any change to the study record content.SummaryDifference0.0%

- Check12 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check48 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check77 days agoChange DetectedA new revision label 'Revision: v3.4.2' was added, and the funding-status notice and 'Revision: v3.4.1' were removed. These are administrative changes that do not alter study information or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedAdded a site-wide funding status notice and updated references to the NIH Clinical Center's operating status, including links to opm.gov. Updated the revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.